Avalo Therapeutics Inc (AVTX) - Long-Term Debt to Capital Coefficient

Avalo Therapeutics, Inc (AVTX) relies on a dedicated staff of scientists specializing in rare pathologies, actively recruiting experts in clinical stages. The business is based on expanding its portfolio of immune agents, including AV-380, for future market capture. The price action, where the indicator stands at 0.00, confirms the complexity of the industry, which requires colossal R&D expenditures and strict patent control.

Avalo Therapeutics, Inc (AVTX) is currently implementing an updated clinical strategy following the acquisition of immunology assets and a business restructuring. This long-term debt-to-equity ratio measures the company's reliance on obligations with maturities exceeding one year relative to its net worth, allowing investors to assess default risk and the overall financial stability of the capital structure during a period of active growth.